title: Cell signaling in NMDA preconditioning and neuroprotection in convulsions induced by quinolinic acid.
abstract: The search for novel, less invasive therapeutic strategies to treat neurodegenerative diseases has stimulated scientists to investigate the mechanisms involved in preconditioning. Preconditioning has been report to occur in many organs and tissues. In the brain, the modulation of glutamatergic transmission is an important and promising target to the use of effective neuroprotective agents. The glutamatergic excitotoxicity is a factor common to neurodegenerative diseases and acute events such as cerebral ischemia, traumatic brain injury and epilepsy. In this review we focus on the neuroprotection and preconditioning by chemical agents. Specially, chemical preconditioning models using N-methyl-d-aspartate (NMDA) pre-treatment, which has demonstrated to lead to neuroprotection against seizures and damage to neuronal tissue induced by quinolinic acid (QA). Here we attempted to gather important results obtained in the study of cellular and molecular mechanisms involved in NMDA preconditioning and neuroprotection.
authors.affiliation: Centro de Biologia Molecular e Estrutural Departamento de Bioquímica CCB, Universidade Federal de Santa Catarina, Florianopolis, SC, Brazil. patsics@gmail.com
authors.forename: Patricia Cardoso
authors.initials: PC
authors.lastname: Severino
authors.forename: Gabriele do Amaral Silva
authors.initials: Gdo A
authors.lastname: Muller
authors.forename: Samuel
authors.initials: S
authors.lastname: Vandresen-Filho
authors.forename: Carla Inês
authors.initials: CI
authors.lastname: Tasca
mesh_terms: D000818:Animals; D001921:Brain / Q000502:physiology*; D001923:Brain Chemistry / Q000502:physiology; D002560:Cerebrovascular Circulation / Q000502:physiology; D018690:Excitatory Amino Acid Agonists / Q000009:adverse effects / Q000494:pharmacology*; D018698:Glutamic Acid / Q000502:physiology; D006801:Humans; D019194:Ischemic Preconditioning; D016202:N-Methylaspartate / Q000009:adverse effects / Q000494:pharmacology*; D018696:Neuroprotective Agents / Q000494:pharmacology*; D020258:Neurotoxicity Syndromes / Q000517:prevention & control; D017378:Quinolinic Acid / Q000633:toxicity*; D016194:Receptors, N-Methyl-D-Aspartate / Q000502:physiology; D018047:Receptors, Purinergic P1 / Q000187:drug effects; D012640:Seizures / Q000139:chemically induced* / Q000517:prevention & control*; D015398:Signal Transduction / Q000502:physiology*
chemical_list: D018690:Excitatory Amino Acid Agonists; D018696:Neuroprotective Agents; D016194:Receptors, N-Methyl-D-Aspartate; D018047:Receptors, Purinergic P1; D018698:Glutamic Acid; D016202:N-Methylaspartate; D017378:Quinolinic Acid